OSI’s Oncology research team has world class capabilities and a proven track record of success. Researchers at OSI first identified and helped develop erlotinib, and identified and progressed into IND track or clinical development the following compounds OSI-930 (2003), OSI-817 (2004), OSI-906 (2005), OSI-027 (2006). The OSI compound collection comprises over 300,000 high quality compounds with drug-like properties.

OSI has 100-plus researchers with combined expertise in:

• High Throughput Screening (HTS) and robotic compound handling
• Biochemistry and enzymology
• Medicinal chemistry
• Structure-based design
• Computational Chemistry
• Drug Metabolism and Pharmacokinetics (DMPK) and Adsorption and Metabolism (ADMET)
• Toxicology
• In vivo and In vitro Pharmacology
• Cell biology and Microscopy
• Signal Transduction Pathways and Molecular Biology
• Molecular Targeted Therapy (MTT) development and Rational design of MTT combinations
• In vivo Imaging
• Non-clinical Translational Research
• Proteomics and tissue profiling using mass spectral and array-based approaches
• Biomarker Discovery and Development

For information on collaborating with OSI, please contact bizdev@osip.com or call (631) 962-2185.